iShares Core S&P 500 ETF vs Personalis Inc. Common Stock — how do they compare? iShares Core S&P 500 ETF trades at $771.2 (market cap $896.46B), while Personalis Inc. Common Stock trades at $15.97 (market cap $1.70B). The key difference: iShares Core S&P 500 ETF is far larger — about 527.3× Personalis Inc. Common Stock's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Personalis Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Personalis Inc. Common Stock for 0 Days on average.
| IVV | PSNL | |
|---|---|---|
Market Cap | $896.46B | $1.70B |
Volume | 4,999,099 | 3,262,398 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $18.38 |
52-Week Low | $634.93 | $5.04 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | — | $1.52B |
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $781.42 with minimal daily movement. Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions. Recent news highlights mixed market sentiment with concerns about profit growth deceleration but optimism for year-end rallies. The ETF maintains its core position as a broad market exposure vehicle with consistent dividend distributions.
The outlook remains cautiously optimistic given the S&P 500's strong institutional support and historical performance. Key opportunities include potential year-end momentum and AI-driven growth in top holdings. Risks center on valuation concerns, profit growth slowdown projections, and market concentration in technology stocks that could amplify volatility during corrections.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →